Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology, Personalized Medicine, Future Medicine

Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology, Personalized Medicine, Future Medicine

Research Article

Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology

Susan Garfield*^,1, Michael P Douglas², Karen V MacDonald³, Deborah A Marshall³ & Kathryn A Phillips²

*Author for correspondence: susan.garfield@gfk.com

Aims: Knowledge of consumer perspectives of personalized medicine (PM) is limited. Our study assessed consumer perspectives of PM, with a focus on oncology care, to inform industry, clinician and payer stakeholders’ programs and policy. Materials & Methods: A nationally representative survey of 602 US consumers’ ≥30 years old explored familiarity, perspectives and expected value of PM. Results: Most (73%) respondents have not heard of ‘personalized medicine,’ though after understanding the term most (95%) expect PM to have a positive benefit. Consumer's willingness to pay is associated with products’ impact on survival, rather than predicting disease risk. If testing indicates consumers are not candidates for oncology therapies, most (84%) would seek a second opinion or want therapy anyway. Conclusions: Understanding heterogeneity in consumer perspectives of PM can inform program and policy development.

Full Text

PDF (1008 KB)

PDF Plus (1023 KB)

Users who read this article also read:

10 years of personalizing medicine: how the incorporation of genomic information is changing practice and policy Amalia M Issa Personalized Medicine, Vol. 12, No. 1, Pages 1-3. Citation | Full Text | PDF (960 KB) | PDF Plus (972 KB) | Add to Favorites | Related

Ethical, legal and social implications of incorporating personalized medicine into healthcare Kyle B Brothers , Mark A Rothstein Personalized Medicine, Vol. 12, No. 1, Pages 43-51. Summary | Full Text | PDF (906 KB) | PDF Plus (943 KB) | Add to Favorites | Related

Clinical players and healthcare payers: aligning perspectives on the cost–effectiveness of next-generation sequencing in oncology Brett Doble , Paula Lorgelly Personalized Medicine, Vol. 12, No. 1, Pages 9-12. Citation | Full Text | PDF (1113 KB) | PDF Plus (1130 KB) | Add to Favorites | Related

‘Someday it will be the norm’: physician perspectives on the utility of genome sequencing for patient care in the MedSeqProject Jason L Vassy , Kurt D Christensen , Melody J Slashinski , Denise M Lautenbach , Sridharan Raghavan ,Jill Oliver Robinson , Jennifer Blumenthal-Barby , Lindsay Zausmer Feuerman , Lisa Soleymani Lehmann, Michael F Murray , Robert C Green , Amy L McGuire Personalized Medicine, Vol. 12, No. 1, Pages 23-32. Summary | Full Text | PDF (992 KB) | PDF Plus (1032 KB) | Add to Favorites | Related